| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Operating Officer
1 company
David Lee Johnson is Chief Operating Officer at VERA. David Lee Johnson's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.4M at current prices.
The VERA filings lean toward selling, a net 2,579 shares.
David Lee Johnson has 9 Form 4 filings on record from May 2022 to February 2026, across 2 companies: Chief Operating Officer at Vera Therapeutics (VERA), 2024–2026; Director at Caribou Biosciences (CRBU), 2022–2026.
The 11 reported transactions were 8 option or other derivative awards, 2 stock awards and 1 open-market sale.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $108K.
The only open-market sale was 2,579 shares of VERA at an average $41.98 on February 23, 2026, about $108K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 23, 2026 | VERA Vera Therapeutics, Inc. | Chief Operating Officer | Sell | 2,579 | $41.98 | $108,276.48 | -5.3% | -18.4% | - |